Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 117-122

  Kanayama, Seiji ^a   Yamada, Yoshihiko ^a   Kawaguchi, Ryuji ^a   Tsuji, Yoriko ^a   Haruta, Shoji ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anoikis; Cyclooxygenase; Endometrial cancer; Hepatocyte growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; MELOXICAM; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; ANOIKIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL STIMULATION; CONTROLLED STUDY; DATA ANALYSIS; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 38749105026     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.117     Document Type: Article

References (46)

1. Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270: 393-400, 1996.
2. Smith WL and Dewitt DL: Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 62: 167-215, 1996.
3. Shao J, Sheng H, Inoue H, Morrow JD and DuBois RN: Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275: 33951-33956, 2000.
4. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT and Subbaramaiah K: Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann NY Acad Sci 952: 109-115, 2001.
5. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
6. Howe LR, Subbaramaiah K, Brown AM and Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8: 97-114, 2001.
7. Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997.
8. Gupta S, Srivastava M, Ahmad N, Bostwick DG and Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78, 2000.
9. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K and Miyazaki K: Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 33: 213-219, 2002.
10. Toyoki H, Fujimoto J, Sato E, Sakaguchi H and Tamaya T: Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers. Ann Oncol 16: 51-55, 2005.
11. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF and Gores GJ: COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35: 552-559, 2002.
12. Tang X, Sun YJ, Half E, Kuo MT and Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903-4908, 2002.
13. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005.
14. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, Mancuso S, Scambia G and Lauriola L: Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 95: 801-807, 2002.
15. Genc S, Attar E, Gurdol F, Kendigelen S, Bilir A and Serdaroglu H: The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture. Clin Exp Med 7: 6-10, 2007.
16. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF and Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802-804, 1991.
17. Jeffers M, Rong S and Woude GF: Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74: 505-513, 1996.
18. Beviglia L, Matsumoto K, Lin CS, Ziober BL and Kramer RH: Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 74: 301-309, 1997.
19. Otte JM, Schmitz F, Kiehne K, Stechele HU, Banasiewicz T, Krokowicz P, Nakamura T, Folsch UR and Herzig K: Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61: 237-246, 2000.
20. Natali PG, Prat M, Nicotra MR, Bigotti A, Olivero M, Comoglio PM and Di Renzo MF: Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 69: 212-217, 1996.
21. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC and Van Waes C: Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918, 2001.
22. Wagatsuma S, Konno R, Sato S and Yajima A: Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 82: 520-530, 1998.
23. Miyata Y, Kanetake H and Kanda S: Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res 12: 4876-4881, 2006.
24. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Wong J, et al: Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 11: 6190-6197, 2005.
25. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Chen Z, et al: Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65: 7071-7080, 2005.
26. Gao M, Fan S, Goldberg ID, Laterra J, Kitsis RN and Rosen EM: Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells. J Biol Chem 276: 47257-47265, 2001.
27. Yoshida S, Harada T, Iwabe T, Taniguchi F, Fujii A, Sakamoto Y, Terakawa N, et al: Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J Clin Endocrinol Metab 87: 2376-2383, 2002.
28. Bae-Jump V, Segreti EM, Vandermolen D and Kauma S: Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol 73: 265-272, 1999.
29. Park YH, Ryu HS, Choi DS, Chang KH, Park DW and Min CK: Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture. Int J Gynecol Cancer 13: 53-60, 2003.
30. Tanaka T, Mizuno K, Umesaki N and Ogita S: Suppressed apoptotic susceptibility in human endometrial epithelial cells pretreated with hepatocyte growth factor. Clin Exp Obstet Gynecol 25: 125-128, 1998.
31. Jones MK, Sasaki E, Halter F, Pai R, Nakamura T, Arakawa T, Kuroki T, et al: HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J 13: 2186-2194, 1999.
32. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS, et al: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999.
33. Zeng Q, McCauley LK and Wang CY: Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem 277: 50137-50142, 2002.
34. Sengupta S, Sellers LA, Cindrova T, Skepper J, Gherardi E, Sasisekharan R, Fan TP, et al: Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res 63: 8351-8359, 2003.
35. McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K and Der CJ: Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol 21: 5488-5499, 2001.
36. Frisch SM: Evidence for a function of death-receptor-related, death-domain-containing proteins in anoikis. Curr Biol 23: 1047-1049, 1999.
37. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Gum KL, Wang CY, et al: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002.
38. Folkman J and Moscona A: Role of cell shape in growth control. Nature 273: 345-349, 1978.
39. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Udagawa Y, et al: Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 26: 1419-1428, 2005.
40. Choi EM, Kwak SJ, Kim YM, Ha KS, Kim JI, Lee SW and Han JA: COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 37: 199-203, 2005.
41. St-Germain ME, Gagnon V, Mathieu I, Parent S and Asselin E: Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol 24: 1311-1324, 2004.
42. Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D and Wang CY: Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem 277: 25203-25208, 2002.
43. Graziani A, Gramaglia D, Cantley LC and Comoglio PM: The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 266: 22087-22090, 1991.
44. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM and Laterra J: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60: 4277-4283, 2000.
45. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
46. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S and Howells L: Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 28: 6013-6020, 1999.